Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $272.6 million.

  • Immunome's Cash & Equivalents rose 7525.39% to $272.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.6 million, marking a year-over-year increase of 7525.39%. This contributed to the annual value of $143.4 million for FY2024, which is 4527.0% up from last year.
  • Immunome's Cash & Equivalents amounted to $272.6 million in Q3 2025, which was up 7525.39% from $143.9 million recorded in Q2 2025.
  • Immunome's 5-year Cash & Equivalents high stood at $272.6 million for Q3 2025, and its period low was $38.4 million during Q2 2023.
  • For the 3-year period, Immunome's Cash & Equivalents averaged around $152.8 million, with its median value being $143.9 million (2025).
  • In the last 5 years, Immunome's Cash & Equivalents soared by 50715.6% in 2024 and then crashed by 1296.3% in 2025.
  • Quarter analysis of 3 years shows Immunome's Cash & Equivalents stood at $98.7 million in 2023, then soared by 45.27% to $143.4 million in 2024, then soared by 90.19% to $272.6 million in 2025.
  • Its Cash & Equivalents stands at $272.6 million for Q3 2025, versus $143.9 million for Q2 2025 and $257.6 million for Q1 2025.